<DOC>
	<DOCNO>NCT00915733</DOCNO>
	<brief_summary>Percutaneous coronary intervention ( PCI ) stent implantation preferred reperfusion strategy treatment acute myocardial infarction ( AMI ) . Despite advance device pharmacological support AMI patient undergo PCI , risk recurrent ischemic event higher elective PCI . Among therapeutic option surmount clopidogrel hyporesponsiveness , high loading dos maintenance dose clopidogrel achieve significant enhancement speed onset intensity inhibition approach widely adapt clinical practice . Interestingly , recent study find carrier loss-of-function hepatic cytochrome ( CYP ) 2C19 allele significantly low level active metabolite clopidogrel , diminish platelet inhibition , high rate major adverse cardiovascular event non-carriers , set PCI acute coronary syndrome ( ACS ) . These finding raise need solution overcome enhance post-clopidogrel platelet reactivity influence loss-of-function CYP2C19 allele . Increasing dose clopidogrel , new potent P2Y12 antagonist ( prasugrel ) , antiplatelet drug cilostazol may alternative antiplatelet regimen patient loss-of-function CYP variant . A recent study demonstrate adjunctive cilostazol dual antiplatelet therapy ( triple antiplatelet therapy ) intensify platelet inhibition compare high maintenance-dose ( MD ) 150 mg/day . Therefore , triple antiplatelet therapy could also alternative antiplatelet therapy improve platelet inhibition clinical outcome carrier CYP2C19 mutant allele . The purpose study determine impact adjunctive cilostazol platelet inhibition carrier non-carriers loss-of-function CYP2C19 allele . The investigator compare enhanced inhibition platelet aggregation adjunctive cilostazol 100 mg twice daily versus high-MD clopidogrel 150 mg/day AMI patient treat emergent coronary stenting , accord CYP2C19 polymorphism .</brief_summary>
	<brief_title>Adjunctive Cilostazol Versus High Maintenance-dose ClopidogrEL Acute Myocardial Infarction ( AMI ) Patients According CYP2C19 Polymorphism</brief_title>
	<detailed_description>- Study timeline : Enrollment period - 6 month ( 2009 . 5.- 2009 . 10 . ) ( Follow-up period - 1 month randomization ) - Stenting , adjunct drug therapy marker myonecrosis 1 ) PCI ( 1 ) All intervention perform accord current standard guideline . ( 2 ) Aspiration thrombectomy dependent operator 's discretion . ( 3 ) If patient multiple lesion , culprit lesion coverage recommend possible . ( 4 ) Any kind DES permit PCI . If bare-metal stent need , permit . ( 5 ) Direct stenting predilation leave operator 's decision . 2 ) Antithrombotic medication 1 . Anticoagulation begin PCI perform low-molecular-weight heparin ( enoxaparin ) unfractionated heparin physician 's discretion . 2 . Only tirofiban administer glycoprotein IIb/IIIa inhibitor ( GPI ) need . 3 ) Markers myonecrosis ( 1 ) Blood sample routinely obtain patient PCI assessment CK-MB 8 , 24 , 48 72 hour . ( 2 ) In case elevate value , measurement repeat every 12 hour peak value reach value normalize . - Assays platelet function 1 ) Blood sample . 1 . Peripheral venous blood sample draw antecubital vein use 21-gauge needle . 2 . Blood sample collect use double-syringe technique , first 2 4 ml blood discard avoid spontaneous platelet activation . 2 ) Light transmittance aggregometry ( LTA ) 1 . Blood sample draw Vacutainer tube contain 0.5 mL sodium citrate 3.2 % ( Becton-Dickinson , San Jose , CA , USA ) process within 60 minute . 2 . Platelet-rich plasma ( PRP ) obtain supernatant fluid centrifuge blood 800 rpm 10 min . The remain blood centrifuge 2,500 rpm 10 min prepare platelet-poor plasma ( PPP ) . PRP adjust platelet count 250,000/μL add PPP need . 3 . Platelet aggregation assess 37℃ use PACKS-4 aggregometer ( Helena Laboratories Corp. , Beaumont , Texas , USA ) . Light transmission adjust 0 % PRP 100 % PPP measurement . 4 . Platelet aggregation systematically measure addition ADP concentration 5 20 μM . Curves record 6 minute . 5 . Aggregation measure laboratory personnel blind group assignment . 6 . Absolute reduction aggregation value ( ∆ Aggmax Agglate ) define change aggregation pre-procedure 30-day therapy : - Agg = pre-procedure Agg - Agg 30-day therapy 7 . Inhibition platelet aggregation ( IPA ) define relative change aggregation value ( Aggmax Agglate ) pre-procedure 30-day therapy : IPA ( % ) = [ ( pre-procedure Agg - Agg 30-day therapy ) /pre-procedure Agg ] X 100 3 ) Rapid platelet function assay ( RPFA : VerifyNow P2Y12 assay ) ( 1 ) A point-of-care system ( VerifyNow ; Accumetrics , San Diego , California ) automate turbidimetric whole blood assay base ability activate platelet use cartridge contain fibrinogen-coated bead platelet agonist . ( 2 ) Blood drawn Greiner Bio-One 3.2 % citrate vacuette tube . ( 3 ) The channel contain fibrinogen-coated polystyrene bead 20 μM ADP platelet agonist . This channel also contain 22 nmol/l PGE1 suppress intracellular free calcium level thereby reduce non-specific contribution P2Y1 receptor . ( 4 ) Results report P2Y12 reaction unit ( PRU ) . ( 5 ) Absolute reduction PRU define change PRU pre-procedure 30-day therapy : - PRU = pre-procedure PRU - PRU 30-day therapy ( 6 ) Percent inhibition ( PI ) PRU define relative change pre-procedure 30-day therapy : PI ( % ) = [ ( pre-procedure PRU - PRU 30-day therapy ) /pre-procedure PRU ] X 100 2-8 . CYP2C19 genotyping 1 . CYP2C19 genotype determine polymerase chain reaction ( PCR ) . SNaPshot method , use genomic DNA isolate leukocytes peripheral venous blood extraction kit ( QIAampR DNA Blood Mini Kit , Qiagen , Hilden , Germany ) . 2 . Two CYP2C19 polymorphism , CYP2C19*2 ( rs4244285 , c. 681G &gt; A , p.P227P ) , CYP2C19*3 ( rs4986893 , c. 636G &gt; A , p. W212X ) , investigate use ABI SNaPshot reaction ABI 3100 automate genetic analyzer ( Applied Biosystems , Foster City , CA , USA ) . - Statistics Data analysis 1 . Sample Size Estimation @ base previous study ( ACCEL-AMI ) Absolute reduction 5 μM ADP-induced maximal aggregation adjunctive cilostazol 30 day : 24.0 % Absolute reduction 5 μM ADP-induced maximal aggregation adjunctive high dose maintenance clopidogrel 150mg/day 30 day : 11.0 % Relative difference enhance platelet inhibition two regimen : 54.0 % - Two-sided α-level = 0.05 - Power = 95 % - Triple group : high-MD group = 1 : 1 - Standard deviation = 0.4 At least 15 patient per group require . @ base previous another study ( CYP2C19 polymorphism study ) The ratio Korean patient carry wild type CYP2C19 v mutant type=4:6 The required patient wild type group : 15 patient The required patient mutant type group : 23 patient Final require patient ( 15+23 ) *2=76 patient 2 . Analysis Continuous variable present mean ± SD compare use Student unpaired Mann-Whitney U test . Categorical variable present number percentage compare use chi-square Fisher 's exact test ( expect frequency &lt; 5 ) . The characteristic platelet function measure 3 group analyze Friedman 's repeat ANOVA rank . After demonstration significant difference among variable ANOVA , post hoc comparison therapy pair make Student-Newman-Keuls procedure multiple comparison . A p value &lt; 0.05 consider indicate significant difference . Statistical analysis perform use commercially available software ( SPSS version 13 ; SPSS Inc. , Chicago , Illinois , USA ) . 3 . Data modulation DSMB ( Data Safety Monitoring Board ) CEC ( Clinical Event Committee )</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Cilostazol</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Platelet Aggregation Inhibitors</mesh_term>
	<criteria>1 . The patient must least 18 year age . 2. clinical symptom compatible acute myocardial ischemia within 12 h admission subsequently document increase cardiac marker . 3 . Measured predischarge platelet reactivity case normalize CKMB value coronary stenting . 1 . A history active bleeding bleeding diatheses . 2 . Oral anticoagulation therapy coumadin . 3 . Contraindication antiplatelet therapy . 4 . LV ejection fraction &lt; 30 % NYHA 3/4 . 5 . Leukocyte count &lt; 3,000/mm3 and/or platelet count &lt; 100,000/mm3 . 6 . AST ALT ≥ 3 time upper normal . 7 . Serum creatinine level ≥ 2.5 mg/dl . 8 . Stroke within 3 month . 9 . Noncardiac disease life expectancy &lt; 1 year . 10 . Inability follow protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>acute myocardial infarction</keyword>
	<keyword>inhibition platelet aggregation</keyword>
	<keyword>triple antiplatelet therapy</keyword>
	<keyword>high maintenance-dose clopidogrel .</keyword>
	<keyword>CYP2C19 polymorphism</keyword>
	<keyword>High posttreatment platelet reactivity</keyword>
	<keyword>Platelet Aggregation Inhibitors</keyword>
	<keyword>CYP2C19 , human</keyword>
</DOC>